NTRK fusion-positive cancers
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
cancer subtype
|
| gptkbp:associatedWith |
gptkb:NTRK1
gptkb:NTRK2 gptkb:NTRK3 |
| gptkbp:clinicalTrialPhase |
NAVIGATE
STARTRK-2 |
| gptkbp:diagnosedBy |
gptkb:FISH
next-generation sequencing immunohistochemistry |
| gptkbp:FDAApproved |
gptkb:entrectinib
gptkb:larotrectinib |
| gptkbp:frequency |
rare
|
| gptkbp:hasBiomarker |
TRK fusion protein
|
| gptkbp:hasMolecularFormula |
gptkb:NTRK_gene_fusion
|
| gptkbp:hasResistanceMechanism |
NTRK kinase domain mutation
bypass signaling pathway activation |
| https://www.w3.org/2000/01/rdf-schema#label |
NTRK fusion-positive cancers
|
| gptkbp:incidence |
less than 1% of all cancers
|
| gptkbp:occurredIn |
gptkb:cancer
gptkb:rhabdomyosarcoma colorectal cancer pediatric cancers |
| gptkbp:prognosis |
variable
|
| gptkbp:target |
gptkb:entrectinib
gptkb:larotrectinib |
| gptkbp:bfsParent |
gptkb:Vitrakvi
|
| gptkbp:bfsLayer |
8
|